pomalidomide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4746 19171-19-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • pomalyst
  • actimid
  • pomalidomide
an immunomodulator with antineoplastic and angiogenesis inhibitor activity
  • Molecular weight: 273.25
  • Formula: C13H11N3O4
  • CLOGP: -0.19
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 109.57
  • ALOGS: -2.03
  • ROTB: 1

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 mg O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Feb. 8, 2013 FDA CELGENE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Plasma cell myeloma 5858.20 20.56 2034 43988 42444 46597596
Death 1322.35 20.56 1632 44390 333916 46306124
Pneumonia 1126.29 20.56 1600 44422 374720 46265320
Full blood count decreased 1091.70 20.56 501 45521 21710 46618330
White blood cell count decreased 847.14 20.56 774 45248 111457 46528583
Neuropathy peripheral 586.11 20.56 575 45447 90318 46549722
Laboratory test abnormal 584.86 20.56 332 45690 22515 46617525
Neutropenia 441.14 20.56 620 45402 142584 46497456
Adverse drug reaction 343.61 20.56 311 45711 44051 46595989
Unevaluable event 308.15 20.56 298 45724 45877 46594163
Thrombosis 283.98 20.56 312 45710 55757 46584283
Platelet count decreased 281.13 20.56 415 45607 99609 46540431
Neutrophil count decreased 279.91 20.56 275 45747 43151 46596889
Fatigue 255.10 20.56 1227 44795 607470 46032570
Plasma cell myeloma recurrent 254.31 20.56 94 45928 2313 46637727
Influenza 234.55 20.56 359 45663 88911 46551129
Rheumatoid arthritis 217.07 20.56 4 46018 240211 46399829
Plasmacytoma 198.17 20.56 79 45943 2398 46637642
Constipation 197.85 20.56 491 45531 173606 46466434
Nasopharyngitis 191.76 20.56 450 45572 153548 46486492
Condition aggravated 182.69 20.56 16 46006 245036 46395004
Human chorionic gonadotropin increased 148.58 20.56 53 45969 1174 46638866
Drug interaction 139.21 20.56 18 46004 203076 46436964
Drug ineffective 127.04 20.56 303 45719 677535 45962505
Bronchitis 112.98 20.56 292 45730 105687 46534353
Infection 112.75 20.56 338 45684 133254 46506786
Drug hypersensitivity 109.14 20.56 52 45970 243773 46396267
Peripheral swelling 98.58 20.56 361 45661 157710 46482330
Full blood count increased 90.65 20.56 34 45988 872 46639168
Muscle spasms 90.50 20.56 297 45725 122816 46517224
Product dose omission issue 88.08 20.56 364 45658 168156 46471884
COVID-19 84.77 20.56 98 45924 18477 46621563
Cytopenia 83.86 20.56 66 45956 7702 46632338
Asthenia 83.39 20.56 558 45464 310517 46329523
Renal disorder 81.03 20.56 115 45907 26571 46613469
Light chain analysis increased 78.03 20.56 32 45990 1046 46638994
Arthralgia 76.21 20.56 153 45869 364450 46275590
Tremor 76.21 20.56 269 45753 115370 46524670
Abdominal pain 75.94 20.56 69 45953 229962 46410078
Cardiac disorder 73.81 20.56 145 45877 43713 46596327
Anaemia 68.58 20.56 459 45563 255320 46384720
Overdose 67.54 20.56 10 46012 101969 46538071
Multiple allergies 65.65 20.56 56 45966 7315 46632725
Vomiting 65.04 20.56 229 45793 452565 46187475
Red blood cell count decreased 62.50 20.56 114 45908 32509 46607531
Headache 62.18 20.56 252 45770 478100 46161940
Psoriasis 61.69 20.56 4 46018 78600 46561440
Hip fracture 58.93 20.56 99 45923 26457 46613583
Urinary tract infection 56.45 20.56 391 45631 219875 46420165
Therapeutic product effect incomplete 55.78 20.56 6 46016 78147 46561893
Blood test abnormal 55.24 20.56 57 45965 9463 46630577
Thrombocytopenia 54.39 20.56 258 45764 126323 46513717
Back pain 53.31 20.56 372 45650 209667 46430373
Product use in unapproved indication 53.01 20.56 12 46010 90261 46549779
Product use issue 52.81 20.56 14 46008 94630 46545410
Plasma cell leukaemia 52.60 20.56 25 45997 1168 46638872
Atrial fibrillation 51.89 20.56 221 45801 103369 46536671
Crystal nephropathy 51.37 20.56 22 46000 803 46639237
Immune system disorder 50.28 20.56 50 45972 7945 46632095
Cataract 48.19 20.56 125 45897 45290 46594750
Sepsis 47.10 20.56 261 45761 135753 46504287
Hyponatraemia 46.21 20.56 21 46001 101311 46538729
Hypercalcaemia 46.08 20.56 78 45944 20968 46619072
Haemoglobin decreased 45.70 20.56 249 45773 128700 46511340
Malaise 45.67 20.56 513 45509 330719 46309321
Rash 44.65 20.56 542 45480 355970 46284070
Seizure 42.88 20.56 35 45987 123019 46517021
Tooth disorder 42.83 20.56 80 45942 23223 46616817
Dizziness 42.82 20.56 518 45504 339896 46300144
Hypokalaemia 42.11 20.56 17 46005 88007 46552033
Wrong technique in product usage process 42.02 20.56 3 46019 54419 46585621
Anxiety 41.77 20.56 72 45950 181885 46458155
Bone pain 41.72 20.56 121 45901 46769 46593271
Respiratory syncytial virus infection 41.57 20.56 36 45986 4799 46635241
Blood count abnormal 41.47 20.56 68 45954 17810 46622230
Renal failure 41.36 20.56 221 45801 113373 46526667
Fall 41.05 20.56 500 45522 328597 46311443
Intentional product use issue 40.50 20.56 3 46019 52777 46587263
Infusion related reaction 40.23 20.56 25 45997 101183 46538857
Drug intolerance 38.19 20.56 262 45760 146787 46493253
Alanine aminotransferase increased 37.79 20.56 20 46002 88431 46551609
Coma 35.80 20.56 7 46015 58342 46581698
Anaphylactic reaction 35.64 20.56 5 46017 53107 46586933
Treatment failure 35.63 20.56 24 45998 93063 46546977
Tachycardia 35.12 20.56 28 45994 99594 46540446
Hospitalisation 34.19 20.56 10 46012 63375 46576665
Deep vein thrombosis 33.80 20.56 162 45860 79611 46560429
Pulmonary thrombosis 33.68 20.56 39 45983 7363 46632677
Respiratory tract infection 33.35 20.56 84 45938 29888 46610152
Aspartate aminotransferase increased 33.32 20.56 18 46004 78682 46561358
Bone lesion 33.17 20.56 32 45990 4899 46635141
Blood calcium increased 32.90 20.56 39 45983 7548 46632492
Pain 32.17 20.56 308 45714 476640 46163400
Electrocardiogram QT prolonged 31.82 20.56 6 46016 51319 46588721
Back disorder 31.67 20.56 42 45980 9099 46630941
Seasonal allergy 31.31 20.56 51 45971 13283 46626757
Monoclonal immunoglobulin present 30.89 20.56 15 46007 735 46639305
Pneumonia influenzal 30.89 20.56 19 46003 1490 46638550
Diarrhoea 29.71 20.56 741 45281 558861 46081179
Cardio-respiratory arrest 29.56 20.56 11 46011 59858 46580182
Agitation 29.42 20.56 9 46013 55406 46584634
Kidney infection 28.83 20.56 56 45966 16733 46623307
Protein total increased 28.68 20.56 22 46000 2471 46637569
Amyloidosis 28.00 20.56 16 46006 1095 46638945
Pancytopenia 27.95 20.56 161 45861 84897 46555143
Monoclonal immunoglobulin increased 27.59 20.56 8 46014 88 46639952
Tooth infection 27.51 20.56 46 45976 12240 46627800
SARS-CoV-2 test positive 26.67 20.56 19 46003 1906 46638134
Off label use 26.56 20.56 243 45779 379598 46260442
International normalised ratio increased 26.02 20.56 7 46015 46876 46593164
Therapeutic product effect decreased 25.78 20.56 26 45996 82575 46557465
Liver function test abnormal 25.69 20.56 7 46015 46480 46593560
Ascites 25.62 20.56 3 46019 36581 46603459
Suicidal ideation 25.21 20.56 12 46010 56370 46583670
Memory impairment 25.16 20.56 146 45876 77191 46562849
Ear infection 25.08 20.56 64 45958 22949 46617091
Product quality issue 24.77 20.56 3 46019 35645 46604395
Bradycardia 24.17 20.56 18 46004 66280 46573760
Swelling face 24.12 20.56 110 45912 52949 46587091
Osteoarthritis 23.72 20.56 16 46006 62009 46578031
Localised infection 23.70 20.56 64 45958 23737 46616303
Pseudomonas aeruginosa meningitis 23.69 20.56 4 46018 0 46640040
Cystitis 23.40 20.56 93 45929 42148 46597892
Cardiac amyloidosis 23.36 20.56 11 46011 503 46639537
Lower limb fracture 23.33 20.56 43 45979 12355 46627685
Dysphonia 23.26 20.56 87 45935 38327 46601713
Hepatic enzyme increased 23.04 20.56 28 45994 81759 46558281
Mobility decreased 22.68 20.56 16 46006 60578 46579462
Peritonitis viral 22.40 20.56 6 46016 48 46639992
Hypoglycaemia 22.18 20.56 13 46009 54336 46585704
Nervousness 22.06 20.56 70 45952 28405 46611635
Malignant neoplasm progression 21.95 20.56 19 46003 64907 46575133
Loss of personal independence in daily activities 21.53 20.56 15 46007 57168 46582872
Fibromyalgia 21.09 20.56 5 46017 36458 46603582
JC virus CSF test positive 20.85 20.56 5 46017 24 46640016
Inappropriate schedule of product administration 20.82 20.56 20 46002 64993 46575047

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Plasma cell myeloma 5844.74 19.58 2412 44335 51050 29854681
Death 1520.98 19.58 2280 44467 355003 29550728
Pneumonia 1399.02 19.58 2118 44629 332188 29573543
Full blood count decreased 827.77 19.58 430 46317 15287 29890444
White blood cell count decreased 662.28 19.58 732 46015 83215 29822516
Laboratory test abnormal 637.11 19.58 375 46372 17067 29888664
Adverse drug reaction 514.20 19.58 364 46383 22781 29882950
Fatigue 481.86 19.58 1334 45413 319339 29586392
Neuropathy peripheral 455.43 19.58 555 46192 69920 29835811
Influenza 441.32 19.58 434 46313 42964 29862767
Unevaluable event 376.59 19.58 346 46401 31439 29874292
Thrombosis 349.17 19.58 378 46369 41853 29863878
Neutropenia 342.16 19.58 671 46076 127869 29777862
Drug interaction 254.99 19.58 14 46733 199554 29706177
Plasma cell myeloma recurrent 243.73 19.58 115 46632 3299 29902432
Peripheral swelling 189.63 19.58 341 46406 60733 29844998
Nasopharyngitis 187.09 19.58 332 46415 58517 29847214
Platelet count decreased 171.32 19.58 455 46292 105674 29800057
Plasmacytoma 159.98 19.58 86 46661 3270 29902461
Infection 153.54 19.58 361 46386 77713 29828018
Neutrophil count decreased 144.62 19.58 247 46500 42207 29863524
Condition aggravated 138.92 19.58 24 46723 137842 29767889
COVID-19 130.35 19.58 150 46597 17728 29888003
Cardiac disorder 127.91 19.58 226 46521 39667 29866064
Constipation 119.04 19.58 417 46330 112489 29793242
Renal disorder 106.25 19.58 156 46591 23428 29882303
Drug intolerance 105.30 19.58 224 46523 45067 29860664
Overdose 104.25 19.58 7 46740 84330 29821401
Tooth disorder 103.09 19.58 97 46650 9064 29896667
Back pain 98.82 19.58 368 46379 102228 29803503
Plasma cell leukaemia 91.02 19.58 39 46708 886 29904845
Deep vein thrombosis 86.15 19.58 248 46499 60253 29845478
Asthenia 84.27 19.58 612 46135 220678 29685053
Sepsis 81.31 19.58 446 46301 145949 29759782
Rash 76.67 19.58 537 46210 191352 29714379
Vomiting 75.36 19.58 143 46604 219675 29686056
Rhabdomyolysis 73.76 19.58 7 46740 63573 29842158
Aspartate aminotransferase increased 73.53 19.58 7 46740 63415 29842316
Localised infection 72.44 19.58 98 46649 13639 29892092
Full blood count increased 72.19 19.58 32 46715 791 29904940
Light chain analysis increased 71.69 19.58 34 46713 986 29904745
Muscle spasms 71.28 19.58 243 46504 64595 29841136
Immune system disorder 69.81 19.58 56 46691 4221 29901510
Hyponatraemia 66.96 19.58 12 46735 67190 29838541
Product dose omission issue 66.28 19.58 301 46446 91330 29814401
Alanine aminotransferase increased 64.50 19.58 18 46729 74258 29831473
Blood count abnormal 62.77 19.58 84 46663 11568 29894163
Acute kidney injury 61.76 19.58 220 46527 273622 29632109
Abdominal pain 61.19 19.58 73 46674 135581 29770150
Monoclonal immunoglobulin present 59.97 19.58 29 46718 879 29904852
Atrial fibrillation 59.68 19.58 329 46418 107795 29797936
Product use in unapproved indication 58.40 19.58 21 46726 73672 29832059
Illness 57.78 19.58 45 46702 3249 29902482
Agitation 57.61 19.58 8 46739 54065 29851666
Malignant neoplasm progression 54.94 19.58 22 46725 72265 29833466
Hypoglycaemia 53.24 19.58 8 46739 50973 29854758
Toxicity to various agents 52.53 19.58 125 46622 177058 29728673
Bronchitis 52.42 19.58 157 46590 38968 29866763
Rheumatoid arthritis 52.14 19.58 3 46744 41194 29864537
Blood test abnormal 48.29 19.58 51 46696 5474 29900257
Hyperkalaemia 47.13 19.58 22 46725 65988 29839743
Intentional product use issue 45.08 19.58 3 46744 36437 29869294
Psoriasis 43.64 19.58 7 46740 42499 29863232
Squamous cell carcinoma of skin 43.62 19.58 62 46685 9033 29896698
Red blood cell count decreased 43.50 19.58 114 46633 26207 29879524
Rib fracture 43.25 19.58 74 46673 12646 29893085
Anxiety 43.07 19.58 46 46701 89825 29815906
Cytopenia 42.16 19.58 58 46689 8198 29897533
Fluid retention 42.06 19.58 109 46638 24889 29880842
Hypokalaemia 42.03 19.58 13 46734 50179 29855552
Headache 41.99 19.58 145 46602 182161 29723570
Arthropathy 41.91 19.58 97 46650 20630 29885101
Suicide attempt 40.11 19.58 5 46742 36692 29869039
Back disorder 39.87 19.58 48 46699 5946 29899785
Upper limb fracture 39.56 19.58 40 46707 4080 29901651
Aggression 38.06 19.58 6 46741 36901 29868830
Pulmonary thrombosis 37.69 19.58 48 46699 6295 29899436
Wrong technique in product usage process 37.29 19.58 3 46744 31152 29874579
International normalised ratio increased 37.14 19.58 14 46733 47725 29858006
Hypotension 37.05 19.58 174 46573 200391 29705340
Dyspnoea 37.01 19.58 727 46020 332568 29573163
Nausea 36.88 19.58 292 46455 296665 29609066
Ascites 36.68 19.58 6 46741 35915 29869816
Electrocardiogram QT prolonged 36.56 19.58 6 46741 35829 29869902
Respiratory tract infection 36.35 19.58 77 46670 15429 29890302
Bone pain 36.25 19.58 87 46660 18939 29886792
Seizure 34.60 19.58 63 46684 98412 29807319
Hip fracture 34.30 19.58 62 46685 11062 29894669
Jaundice 34.14 19.58 5 46742 32481 29873250
Cardio-respiratory arrest 33.91 19.58 24 46723 57282 29848449
Malaise 33.52 19.58 403 46344 166559 29739172
Interstitial lung disease 33.33 19.58 27 46720 60170 29845561
Coronary artery disease 33.33 19.58 18 46729 49694 29856037
General physical health deterioration 33.30 19.58 66 46681 99878 29805853
Protein total increased 32.88 19.58 27 46720 2103 29903628
Hospitalisation 32.84 19.58 14 46733 44305 29861426
Balance disorder 32.66 19.58 128 46619 36365 29869366
Cataract 32.49 19.58 91 46656 21744 29883987
Bone lesion 31.56 19.58 29 46718 2628 29903103
Blood calcium increased 31.54 19.58 31 46716 3056 29902675
Pancreatitis 31.37 19.58 9 46738 36481 29869250
Coma 31.23 19.58 12 46735 40437 29865294
Cardiac arrest 31.21 19.58 61 46686 92789 29812942
Lower respiratory tract infection 30.99 19.58 102 46645 26612 29879119
Drug reaction with eosinophilia and systemic symptoms 30.85 19.58 4 46743 28484 29877247
Sinusitis 30.69 19.58 118 46629 33227 29872504
Hypercalcaemia 30.40 19.58 63 46684 12432 29893299
Blood urea increased 30.40 19.58 6 46741 31375 29874356
Lactic acidosis 30.17 19.58 6 46741 31207 29874524
Depressed level of consciousness 30.08 19.58 11 46736 38211 29867520
Body height decreased 30.05 19.58 33 46714 3701 29902030
Melaena 29.80 19.58 7 46740 32430 29873301
Neutropenic sepsis 29.51 19.58 59 46688 11350 29894381
Spinal fracture 29.46 19.58 44 46703 6704 29899027
Fall 29.40 19.58 422 46325 181450 29724281
White blood cell count abnormal 29.37 19.58 28 46719 2658 29903073
Dysarthria 29.18 19.58 6 46741 30484 29875247
Gastric disorder 29.06 19.58 56 46691 10487 29895244
Injection site pain 28.93 19.58 6 46741 30304 29875427
Gastrointestinal haemorrhage 28.76 19.58 54 46693 83392 29822339
Inappropriate schedule of product administration 28.72 19.58 13 46734 39715 29866016
SARS-CoV-2 test positive 28.11 19.58 22 46725 1600 29904131
Blood bilirubin increased 28.07 19.58 11 46736 36625 29869106
Tachycardia 27.88 19.58 45 46702 73694 29832037
Gamma-glutamyltransferase increased 27.63 19.58 6 46741 29344 29876387
Haematuria 27.56 19.58 18 46729 44816 29860915
Musculoskeletal disorder 27.49 19.58 36 46711 4853 29900878
Multiple allergies 26.65 19.58 24 46723 2119 29903612
Metabolic acidosis 25.94 19.58 13 46734 37448 29868283
Tooth infection 25.80 19.58 36 46711 5155 29900576
Drug hypersensitivity 25.73 19.58 42 46705 68477 29837254
Cerebral toxoplasmosis 25.58 19.58 20 46727 1452 29904279
Respiratory arrest 25.55 19.58 7 46740 29251 29876480
Angioedema 25.25 19.58 11 46736 34373 29871358
Incorrect dose administered 25.14 19.58 9 46738 31677 29874054
Blood immunoglobulin M increased 24.79 19.58 10 46737 194 29905537
Bradycardia 24.76 19.58 40 46707 65486 29840245
Acute myocardial infarction 24.36 19.58 28 46719 52911 29852820
Arthralgia 24.34 19.58 119 46628 135672 29770059
Hepatic function abnormal 24.25 19.58 18 46729 41927 29863804
Respiration abnormal 24.18 19.58 25 46722 2617 29903114
Agranulocytosis 23.95 19.58 3 46744 21939 29883792
Ear infection 23.89 19.58 42 46705 7332 29898399
Haematemesis 23.39 19.58 6 46741 26197 29879534
Psychotic disorder 23.34 19.58 3 46744 21512 29884219
Shock 22.93 19.58 4 46743 22855 29882876
Blood pressure abnormal 22.85 19.58 40 46707 6959 29898772
Pyrexia 22.25 19.58 609 46138 293880 29611851
Seasonal allergy 22.20 19.58 32 46715 4721 29901010
Blood creatinine increased 22.15 19.58 71 46676 91304 29814427
Hypoacusis 22.10 19.58 60 46687 14079 29891652
Blood lactate dehydrogenase increased 22.05 19.58 3 46744 20598 29885133
Lower limb fracture 21.99 19.58 28 46719 3671 29902060
White blood cell disorder 21.73 19.58 17 46730 1235 29904496
Blood alkaline phosphatase increased 21.69 19.58 11 46736 31476 29874255
Transaminases increased 21.67 19.58 5 46742 23452 29882279
Encephalopathy 21.09 19.58 12 46735 32193 29873538
Oxygen saturation decreased 21.06 19.58 22 46725 43418 29862313
Sinus disorder 20.88 19.58 36 46711 6189 29899542
Clostridium difficile infection 20.81 19.58 63 46684 15720 29890011
Spinal disorder 20.72 19.58 26 46721 3359 29902372
Mucosal inflammation 20.49 19.58 11 46736 30483 29875248
White blood cell count increased 20.49 19.58 19 46728 39654 29866077
Ventricular tachycardia 20.30 19.58 6 46741 23856 29881875
Gastrointestinal infection 20.06 19.58 27 46720 3738 29901993
Drug ineffective 20.00 19.58 393 46354 339994 29565737
Hepatic enzyme increased 19.85 19.58 14 46733 33480 29872251
Vertebral lesion 19.84 19.58 8 46739 155 29905576

Pharmacologic Action:

SourceCodeDescription
ATC L04AX06 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Other immunosuppressants
MeSH PA D020533 Angiogenesis Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D006131 Growth Inhibitors
MeSH PA D006133 Growth Substances
MeSH PA D007155 Immunologic Factors
FDA EPC N0000184014 Thalidomide Analog
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:48422 angiostatic agents
CHEBI has role CHEBI:50846 biomodulator

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Multiple myeloma indication 109989006 DOID:9538

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.84 acidic
pKa2 1.86 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
1MG POMALYST CELGENE N204026 Feb. 8, 2013 RX CAPSULE ORAL Nov. 20, 2023 ADDITIONULLL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
2MG POMALYST CELGENE N204026 Feb. 8, 2013 RX CAPSULE ORAL Nov. 20, 2023 ADDITIONULLL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
3MG POMALYST CELGENE N204026 Feb. 8, 2013 RX CAPSULE ORAL Nov. 20, 2023 ADDITIONULLL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
4MG POMALYST CELGENE N204026 Feb. 8, 2013 RX CAPSULE ORAL Nov. 20, 2023 ADDITIONULLL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
1MG POMALYST CELGENE N204026 Feb. 8, 2013 RX CAPSULE ORAL May 20, 2024 PEDIATRIC EXCLUSIVITY
2MG POMALYST CELGENE N204026 Feb. 8, 2013 RX CAPSULE ORAL May 20, 2024 PEDIATRIC EXCLUSIVITY
3MG POMALYST CELGENE N204026 Feb. 8, 2013 RX CAPSULE ORAL May 20, 2024 PEDIATRIC EXCLUSIVITY
4MG POMALYST CELGENE N204026 Feb. 8, 2013 RX CAPSULE ORAL May 20, 2024 PEDIATRIC EXCLUSIVITY
1MG POMALYST CELGENE N204026 Feb. 8, 2013 RX CAPSULE ORAL May 14, 2027 FOR THE TREATMENT OF KAPOSI SARCOMA (KS) IN ADULT PATIENTS WHO ARE HIV-NEGATIVE
1MG POMALYST CELGENE N204026 Feb. 8, 2013 RX CAPSULE ORAL May 14, 2027 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSI SARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
2MG POMALYST CELGENE N204026 Feb. 8, 2013 RX CAPSULE ORAL May 14, 2027 FOR THE TREATMENT OF KAPOSI SARCOMA (KS) IN ADULT PATIENTS WHO ARE HIV-NEGATIVE
2MG POMALYST CELGENE N204026 Feb. 8, 2013 RX CAPSULE ORAL May 14, 2027 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSI SARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
3MG POMALYST CELGENE N204026 Feb. 8, 2013 RX CAPSULE ORAL May 14, 2027 FOR THE TREATMENT OF KAPOSI SARCOMA (KS) IN ADULT PATIENTS WHO ARE HIV-NEGATIVE
3MG POMALYST CELGENE N204026 Feb. 8, 2013 RX CAPSULE ORAL May 14, 2027 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSI SARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
4MG POMALYST CELGENE N204026 Feb. 8, 2013 RX CAPSULE ORAL May 14, 2027 FOR THE TREATMENT OF KAPOSI SARCOMA (KS) IN ADULT PATIENTS WHO ARE HIV-NEGATIVE
4MG POMALYST CELGENE N204026 Feb. 8, 2013 RX CAPSULE ORAL May 14, 2027 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSI SARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
1MG POMALYST CELGENE N204026 Feb. 8, 2013 RX CAPSULE ORAL Nov. 14, 2027 PEDIATRIC EXCLUSIVITY
2MG POMALYST CELGENE N204026 Feb. 8, 2013 RX CAPSULE ORAL Nov. 14, 2027 PEDIATRIC EXCLUSIVITY
3MG POMALYST CELGENE N204026 Feb. 8, 2013 RX CAPSULE ORAL Nov. 14, 2027 PEDIATRIC EXCLUSIVITY
4MG POMALYST CELGENE N204026 Feb. 8, 2013 RX CAPSULE ORAL Nov. 14, 2027 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Protein cereblon Cytosolic other MODULATOR EC50 6.58 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
D08976 KEGG_DRUG
4032092 VANDF
C2347625 UMLSCUI
CHEBI:72690 CHEBI
134780 PUBCHEM_CID
CHEMBL43452 ChEMBL_ID
DB08910 DRUGBANK_ID
C467566 MESH_SUPPLEMENTAL_RECORD_UI
7348 IUPHAR_LIGAND_ID
8873 INN_ID
D2UX06XLB5 UNII
1369713 RXNORM
199372 MMSL
29234 MMSL
d08041 MMSL
014897 NDDF
703789000 SNOMEDCT_US
703790009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Pomalyst HUMAN PRESCRIPTION DRUG LABEL 1 59572-501 CAPSULE 1 mg ORAL NDA 35 sections
Pomalyst HUMAN PRESCRIPTION DRUG LABEL 1 59572-502 CAPSULE 2 mg ORAL NDA 35 sections
Pomalyst HUMAN PRESCRIPTION DRUG LABEL 1 59572-503 CAPSULE 3 mg ORAL NDA 35 sections
Pomalyst HUMAN PRESCRIPTION DRUG LABEL 1 59572-504 CAPSULE 4 mg ORAL NDA 35 sections